I. MODIFIED AGREEMENTS |
|||
Biotech Co.* | Pharma Co. | Change from | Terms/Details (Date) |
| | |||
Anika | Boehringer | Renewed contract to market Anika's Hyvisc product | The contract extends exclusive U.S. marketing rights to Boehringer through May 2006 (6/26) |
Athersys | Bristol-Myers | Expanded collaboration for three more years to deliver cell lines that Bristol-Myers will use in its drug screening program | Athersys will agree with Squibb on certain validated targets and deliver cell lines that express the targets; Squibb will use combinatorial chemistry expertise to develop small-molecule drug candidates; Athersys will receive license fees for each target cell line, milestone payments and potential royalties (8/5) |
Boston | Natural Pharmaceuticals | Extension of the exclusive paclitaxel supply relationship | Boston Scientific acquired additional shares in Natural; terms of the agreement were not disclosed (7/9) |
Compugen | Novartis AG (Switzerland) | Expanded collaboration, centered on the identification of drug targets, to include target validation | The companies will collaborate on the research and development of a large-scale RNA interference platform (9/4) |
Compugen | Pfizer Global | Extended collaboration | The continuation agreement provides Pfizer with LEADS, Compugen's computational biology platform for drug discovery, and A4000 and Z3, 2-D gel analysis software packages for advanced proteomic analysis (7/22) |
Debiopharm SA* (Switzerland) | Sanofi-Synthelabo | Extended patent and knowledge agreement on Eloxatin (oxaliplatin) | Debiopharm and Sanofi-Synthelabo will share development costs for improvements to the available formulations of Eloxatin, new indications and new methods of use for Eloxatin; Sanofi has worldwide marketing rights for the product, excluding Japan, Argentina, Paraguay, Uruguay and India (8/27) |
Exelixis Inc. | Bristol-Myers | Two-year extended mechanism-of-action collaboration | Exelixis uses its platform and comparative genetics and functional genomics knowledge to identify targets of compounds delivered by Bristol-Myers (8/6) |
Galapagos | Bayer AG | Expanded functional genomics collaboration | Galapagos will provide Bayer with adenoviral vectors containing human genes selected by Bayer (7/10) |
Galapagos | Procter & Gamble Pharmaceuticals (division of Procter | Broadened collaboration to use Galapagos' adenoviral gene expression technology | The technology will be used to validate the use of genes as drug targets in endocrinology, cardiovascular and musculoskeletal diseases (9/3) |
NeuroSearch A/S* (Denmark) | Abbott | Extended agreement to discover, develop and commercialize compounds for the treatment of central and peripheral nervous system disorders | Abbott gains exclusive worldwide sales rights to compounds resulting from the collaboration (8/16) |
Pharmagene | AstraZeneca | Expanded agreement to | The deal expands the number of targets to be investigated and the range of human tissues to be tested (7/3**) |
Pharsight | NV Organon | Agreement in which | Pending the outcome of the initial project, Pharsight and Organon plan to implement Pharsight processes and technology for broader use at Organon (8/20) |
Quark Biotech | Fujisawa | Broadened research collaboration into drug discovery to treat stroke | Quark will construct bioassays on target proteins selected by both Fujisawa and Quark and will perform high-throughput screening of the chemical libraries based on the bioassays developed; Quark also will continue the gene discovery and target validation program set forth under the original agreement; Fujisawa has increased research funding to Quark to cover the additional work (8/6) |
SciTegic | Chugai Pharma | Renewed license of SciTegic's Pipeline Pilot software to enhance high-throughput screening for therapeutic products to treat cardiovascular diseases and cancer | Financial terms were not disclosed (7/15) |
Versicor Inc. | Novartis AG | Extended deal for | The deal begun in April 1999 is extended for another year; it focuses on antibacterials that inhibit deformylase and the Mur pathway (7/17) |
Versicor Inc. | Pharmacia | Extended deal for antibiotics | The deal begun in April 1999 is extended for three years; it focuses on oxazolidinones (7/17) |
V.I. Tech- | Pall Corp. | Modified worldwide collaboration for the Inactine red blood cell pathogen- inactivation system | Pall will relinquish its exclusive distribution rights in return for a cap on its financial commitments to the program and royalties upon commercialization (8/7) |
II. TERMINATED AGREEMENTS | |||
DOR Bio- | Elan Corp. | Terminated joint ventures, InnoVaccines Corp. and Endorex Newco Ltd. | The companies terminated the two joint ventures (7/2) |
DUSA | Schering AG | Terminated agreement for the rights to Levulan PDT | DUSA reacquired the rights to Levulan PDT in the dermatology field; Schering will continue its financial support for the dermatology program for the remainder of 2002 and will complete several ongoing clinical studies for DUSA (8/27) |
Onyx Pharma- | Pfizer Inc. | Terminated agreement for the rights to ONYX-015 | Onyx regained full rights to the cancer therapeutic; the deal was first signed in September 1999 and was worth about $155M (9/17) |
OSI Pharma- | Anaderm Research Corp. (subsidiary | Terminated research alliance in cosmeceuticals | OSI agreed to end early its funded research alliance; Pfizer will pay OSI an $8M "wind-down fee," in return for OSI transferring to Pfizer the research it has amassed since the alliance began in 1999; OSI wants to focus on oncology (7/17) |
Triangle Pharmaceuticals | Abbott | Terminated rights | Triangle reacquired full rights to the candidates, including Coviracil for HIV (7/31) |
ViroPharma | Aventis | Terminated agreement to develop Picovir | ViroPharma is returning $20M in advance milestone pyaments to Aventis, which in turn will pay back ViroPharma for Aventis' share of development and commercial costs, as well as ViroPharma's detailing fees through August; Aventis also bought 3M shares of ViroPharma stock for $4.6M as part of the termination deal (8/1) |
Zonagen Inc. | Schering-Plough | Terminated worldwide | Schering-Plough has made more than $20M in milestone payments in the deal; it returned all rights to the phentolamine- based products, its combination products, patent rights, know-how and trademarks for the treatment of sexual dysfunction in men and women (7/15) |
| | |||
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
** Denotes the date the item ran in BioWorld International. | |||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange | |||
